Tenax Therapeutics, Inc.
TENX
$6.00
-$0.04-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.53M | 11.21M | 6.78M | 5.73M | 5.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.04M | 26.92M | 19.49M | 15.54M | 13.04M |
| Operating Income | -35.04M | -26.92M | -19.49M | -15.54M | -13.04M |
| Income Before Tax | -31.48M | -24.21M | -17.60M | -14.56M | -12.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.48 | -24.21 | -17.60 | -14.56 | -12.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.48M | -24.21M | -17.60M | -14.56M | -12.57M |
| EBIT | -35.04M | -26.92M | -19.49M | -15.54M | -13.04M |
| EBITDA | -11.91M | -15.58M | -19.49M | -15.53M | -13.03M |
| EPS Basic | -3.26 | -2.47 | -5.31 | -15.92 | -22.35 |
| Normalized Basic EPS | -2.04 | -1.55 | -3.32 | -9.96 | -13.97 |
| EPS Diluted | -3.26 | -2.47 | -5.31 | -15.92 | -22.35 |
| Normalized Diluted EPS | -2.04 | -1.55 | -3.32 | -9.96 | -13.97 |
| Average Basic Shares Outstanding | 97.19M | 95.00M | 59.63M | 24.64M | 3.77M |
| Average Diluted Shares Outstanding | 97.19M | 95.00M | 59.63M | 24.64M | 3.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |